Dashboard
Financial statements
ZTS

Company financials

Zoetis

Health Care Pharmaceuticals Parsippany, New Jersey Last filing Feb 12, 2026 · FY2025
Revenue FY2025
$9.5B
3y CAGR +5.4% P51
Net income FY2025
$2.7B
Net margin +28.2% P90
Total assets FY2025
$15.5B
ROA +17.2% P93
Operating cash flow FY2025
$2.9B
FCF margin +24.1% P84
15 yrs · FY2011–FY2025 8 filed · 0 derived · 1 blank

Balance Sheet

Assets, liabilities, and equity

30 accounts · 3 years
Total assets $15.5B
Total liabilities $12.1B
Shareholders equity $3.3B
Account 2025 2024 2023 Trend
Assets
Cash and Cash Equivalents $2.3B 16.4% $2.0B -2.6% $2.0B
Accounts Receivable $1.6B 20.8% $1.3B 0.9% $1.3B
Inventory $2.4B 5.4% $2.3B -10.1% $2.6B
Other Current Assets $436.0M 15.6% $377.0M -13.1% $434.0M
Total Current Assets $6.8B 13.1% $6.0B -5.6% $6.3B
Property,Plant and Equipment $3.7B 8.6% $3.4B 5.8% $3.2B
Operating Lease Assets $288.0M 31.5% $219.0M -4.8% $230.0M
Goodwill $2.8B 1.6% $2.7B -1.3% $2.8B
Intangible Assets $998.0M -11.4% $1.1B -15.8% $1.3B
Deferred Tax Assets $637.0M 18.0% $540.0M 162.1% $206.0M
Other Noncurrent Assets $328.0M 31.2% $250.0M 21.4% $206.0M
Total Assets $15.5B 9.2% $14.2B -0.7% $14.3B
Liabilities
Accounts Payable $487.0M 12.5% $433.0M 5.4% $411.0M
Accrued Liabilities $1.6B 9.1% $1.5B 9.5% $1.4B
Current Portion of Long Term Debt $0 -100.0% $1.4B 44900.0% $3.0M
Other Current Liabilities $107.0M -14.4% $125.0M 22.5% $102.0M
Total Current Liabilities $2.2B -34.5% $3.4B 80.6% $1.9B
Long Term Debt $9.0B 73.2% $5.2B -20.5% $6.6B
Operating Lease Liabilities Noncurrent $196.0M 12.6% $174.0M -7.4% $188.0M
Deferred Tax Liabilities $139.0M -16.8% $167.0M 14.4% $146.0M
Other Noncurrent Liabilities $524.0M 6.1% $494.0M -2.8% $508.0M
Total Liabilities $12.1B 28.2% $9.5B 1.9% $9.3B
Equity
Common Stock $5.0M 0.0% $5.0M 0.0% $5.0M
Additional Paid In Capital $1.1B -6.9% $1.2B 4.3% $1.1B
Retained Earnings $13.7B 14.8% $12.0B 16.3% $10.3B
Treasury Stock $10.7B 43.5% $7.4B 33.0% $5.6B
Accumulated Other Comprehensive Income $-834.0M 11.3% $-940.0M -12.0% $-839.0M
Total Stockholders Equity $3.3B -30.2% $4.8B -4.5% $5.0B
Noncontrolling Interest $0 $0 100.0% $-6.0M
Total Liabilitiesand Equity $15.5B 8.6% $14.2B -0.3% $14.3B

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 3 years
Ratio 2025 2024 2023
Profitability
Gross margin +71.8% +70.6% +70.0%
Operating margin — — —
Net margin +28.2% +26.9% +27.4%
FCF margin +24.1% +24.8% +19.0%
Growth
Revenue CAGR (3y) +5.4% +6.0% +8.6%
Returns
ROE +80.2% +52.1% +46.9%
ROA +17.2% +17.5% +16.4%
ROIC — — —
Liquidity
Current ratio 3.03x 1.75x 3.36x
Quick ratio 1.75x 0.97x 1.77x
Leverage
D/E 3.64x 1.98x 1.86x
Interest coverage — — —
Efficiency
Asset turnover 0.61x 0.65x 0.60x
Cash conversion cycle +327d +303d +363d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds ZTS to your watchlist.